trending Market Intelligence /marketintelligence/en/news-insights/trending/x52xal146lybdysulvehhg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Sucampo upsizes note offering to $260M

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Sucampo upsizes note offering to $260M

Sucampo Pharmaceuticals Inc. priced and upsized a previously announced debt offering to repay an existing senior secured credit facility.

The company will issue $260 million worth of 3.25% senior notes due 2021, complete with an option to purchase an additional $40 million worth of the debt.

Interest will be payable semiannually starting June 15, 2017. The notes will also convert into class A Sucampo shares at an initial conversion rate of $16.59 per share.

Sucampo initially planned on issuing $225 million of the debt.

Sucampo Pharmaceuticals secured a $250 million credit facility in October 2015 to fund its planned purchase of R-Tech Ueno. The new debt issue could help free up some of the company's cash, given that Sucampo is required to maintain at least $25 million in a restricted cash account until at least $35 million of the facility is repaid or prepaid.

Leerink Partners LLC is the sole book-running manager of the issue. The sale is expected to close Dec. 27.